A report has surfaced regarding an unusual request for access to Eli Lilly's experimental obesity drug, retatrutide, raising questions about the identity of the patient involved. The drug is currently in development and has not yet been approved for widespread use. The situation has led to speculation that the patient could be former U.S. President Donald Trump, though no confirmation has been provided.
According to a report from a far-right outlet, the request for the drug has sparked public interest and discussion. The report does not provide direct evidence linking Trump to the request but notes that the matter has become a point of conversation among some political observers.
A separate account from a lean-left outlet adds further context. It states that a White House spokesperson denied the involvement of Trump in the case, but only after the story had already been published. This sequence of events has led to questions about the timing and nature of the denial.
The situation remains under scrutiny, with no further official statements being released. The experimental nature of the drug and the lack of public information about the patient have contributed to ongoing speculation. No additional details about the patient's identity or medical condition have been disclosed.
The White House has not provided further clarification, and no new developments have been reported at this time. The focus remains on the unusual circumstances surrounding the request and the responses from official sources.
Read the original coverage
💬 Comments
📜 Comment Policy